BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 18007663)

  • 1. Molecular characteristics of immunogenic cancer cell death.
    Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
    Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
    Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor stress, cell death and the ensuing immune response.
    Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
    Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of tumor cell death.
    Kepp O; Tesniere A; Zitvogel L; Kroemer G
    Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic cell death modalities and their impact on cancer treatment.
    Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
    Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Witch hunt against tumor cells enhanced by dendritic cells.
    Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
    Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecto-calreticulin in immunogenic chemotherapy.
    Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
    Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
    Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
    Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From regulation of dying cell engulfment to development of anti-cancer therapy.
    Krysko DV; Vandenabeele P
    Cell Death Differ; 2008 Jan; 15(1):29-38. PubMed ID: 18007662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
    Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
    Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.
    van der Most RG; Currie AJ; Robinson BW; Lake RA
    Cell Death Differ; 2008 Jan; 15(1):13-20. PubMed ID: 18007666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High hydrostatic pressure induces immunogenic cell death in human tumor cells.
    Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R
    Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory functions of membrane-bound and exported heat shock protein 70.
    Radons J; Multhoff G
    Exerc Immunol Rev; 2005; 11():17-33. PubMed ID: 16385841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
    Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
    J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells and innate defense against tumor cells.
    Ullrich E; Ménard C; Flament C; Terme M; Mignot G; Bonmort M; Plumas J; Chaperot L; Chaput N; Zitvogel L
    Cytokine Growth Factor Rev; 2008 Feb; 19(1):79-92. PubMed ID: 18155952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
    Kepp O; Galluzzi L; Martins I; Schlemmer F; Adjemian S; Michaud M; Sukkurwala AQ; Menger L; Zitvogel L; Kroemer G
    Cancer Metastasis Rev; 2011 Mar; 30(1):61-9. PubMed ID: 21249425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGB1: a two-headed signal regulating tumor progression and immunity.
    Campana L; Bosurgi L; Rovere-Querini P
    Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic cells induce HMGB1 release from melanoma cell lines.
    Ito N; DeMarco RA; Mailliard RB; Han J; Rabinowich H; Kalinski P; Stolz DB; Zeh HJ; Lotze MT
    J Leukoc Biol; 2007 Jan; 81(1):75-83. PubMed ID: 16968820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.
    Aymeric L; Apetoh L; Ghiringhelli F; Tesniere A; Martins I; Kroemer G; Smyth MJ; Zitvogel L
    Cancer Res; 2010 Feb; 70(3):855-8. PubMed ID: 20086177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.